| Item Type | Name |
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
|
Academic Article
|
Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
|
|
Academic Article
|
Infliximab for the treatment of fistulas in patients with Crohn's disease.
|
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Updating the approach to Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
|
Academic Article
|
Biologics in peri-operative management of Crohn's disease.
|
|
Academic Article
|
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
|
|
Academic Article
|
Evolutionary biologic therapy for inflammatory bowel disease.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Considerations in the management of steroid-dependent Crohn's disease.
|
|
Academic Article
|
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
A lupus-like syndrome associated with infliximab therapy.
|
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
|
Academic Article
|
Emerging biologic therapies in inflammatory bowel disease.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease.
|
|
Academic Article
|
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
|
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
|
Academic Article
|
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
|
|
Academic Article
|
Crohn's disease arthritis treated with infliximab: an open trial in four patients.
|
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
|
Academic Article
|
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
|
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
|
Academic Article
|
Management of inflammatory bowel disease: past, present and future.
|
|
Academic Article
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
|
Academic Article
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
What to take from TREAT?
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
|
Academic Article
|
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
|
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
|
Academic Article
|
Infliximab or cyclosporine for severe ulcerative colitis.
|
|
Academic Article
|
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
|
|
Academic Article
|
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
|
|
Academic Article
|
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
|
|
Academic Article
|
Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
|
|
Academic Article
|
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
|
|
Academic Article
|
A Never Ending STORI.
|
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis.
|
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|
|
Academic Article
|
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis.
|
|
Concept
|
Infliximab
|
|
Academic Article
|
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
|